Chapman J W, Mobbs B G, McCready D R, Lickley H L, Trudeau M E, Hanna W, Kahn H J, Sawka C A, Fish E B, Pritchard K I
Henrietta Banting Breast Centre, Women's College Hospital, Toronto, Ontario, Canada.
J Steroid Biochem Mol Biol. 1996 Mar;57(5-6):323-8. doi: 10.1016/0960-0760(95)00275-8.
Oestrogen and progesterone receptor (ER and PgR) assay values are frequently used in medical decision-making for breast cancer patients. We have proposed statistical standardization of receptor assay values to improve inter-laboratory comparability, and now report the use of standardized log units (SLU) to investigate the effects of ER and PgR cut-points on time to first recurrence outside the breast (DFS). Between 1980 and 1986, there were 678 primary breast cancer patients treated at the Henrietta Banting Breast Centre (HBBC). The effects of ER and PgR cut-points were examined with multivariate analyses considering the variables: age, tumour size, nodal status, weight and adjuvant treatment. We considered receptor assay cut-points ranging from - 1.0 to + 1.0 SLU (ER between 7 and 166 fmol/mg protein; PgR between 7 and 181 fmol/mg protein). PgR was included in the multivariate prognostic models more often than ER, although patients had a better prognosis with both larger ER and PgR values. There was no best cut-point for ER or PgR, and there was strong evidence that ER and PgR should be considered as continuous rather than dichotomous (negative, positive) variables. Patient prognosis should also be more comparable with SLU.
雌激素和孕激素受体（ER和PgR）检测值常用于乳腺癌患者的医疗决策。我们提出了受体检测值的统计标准化方法，以提高实验室间的可比性，现在报告使用标准化对数单位（SLU）来研究ER和PgR切点对首次出现乳腺外复发时间（无病生存期，DFS）的影响。1980年至1986年间，有678例原发性乳腺癌患者在亨丽埃塔·班廷乳腺中心（HBBC）接受治疗。在多变量分析中，考虑年龄、肿瘤大小、淋巴结状态、体重和辅助治疗等变量，研究了ER和PgR切点的影响。我们考虑的受体检测切点范围为-1.0至+1.0 SLU（ER为7至166 fmol/mg蛋白；PgR为7至181 fmol/mg蛋白）。尽管ER和PgR值越大患者预后越好，但PgR比ER更常被纳入多变量预后模型。ER或PgR没有最佳切点，并且有充分证据表明应将ER和PgR视为连续变量而非二分变量（阴性、阳性）。患者预后使用SLU也应更具可比性。
